Advancing cardiovascular risk evaluation with Diazyme Lp(a) Assay

The Diazyme Lipoprotein(a) Assay enables quantitative measurement of lipoprotein(a) [Lp(a)] in human serum or plasma using routine clinical chemistry analyzers. The assay utilizes a latex-enhanced immunoturbidimetric method, in which Lp(a) particles in the sample bind to antibodies coated on latex particles, forming agglutination that is measured photometrically. The resulting signal is directly proportional to the concentration of Lp(a), which allows laboratories to incorporate Lp(a) testing into cardiovascular risk evaluation workflows.

Why choose the Diazyme Lp(a) Assay?

• Rapid turnaround time: Delivers results in less than 10 minutes, supporting efficient laboratory workflows.
• Low sample volume: Requires only 6 μL of serum or plasma, allowing testing even when sample availability is limited.
• Liquid-stable reagent format: A dual-vial liquid reagent system simplifies handling and preparation in the laboratory.
• Automated immunoturbidimetric method: Provides quantitative measurement of Lp(a) concentrations with reliable analytical performance.

Measurement of Lp(a) can provide important insight when evaluating lipid metabolism disorders and assessing risk associated with atherosclerotic cardiovascular disease. With rapid assay time and compatibility with routine clinical chemistry analyzers, the Diazyme Lp(a) Assay offers laboratories a practical solution for expanding cardiovascular biomarker testing while maintaining operational efficiency. Designed for routine chemistry analyzers: Enables laboratories to perform Lp(a) testing without requiring specialized instrumentation.

Read the full May-June issue of CLN.

Industry Insights articles are created and paid for by advertisers. The views expressed in these articles do not necessarily represent ADLM's views, and their inclusion in CLN is not an endorsement by CLN or ADLM.